Antibodies specific for LOX1 and use in treatment of cardiovascular disorders

Patent metadata

Field	Value
Publication number	US-10117889-B2
Application number	US-201515516115-A
Country	US
Kind code	B2
Filing date	Sep 30, 2015
Priority date	Oct 1, 2014
Publication date	Nov 6, 2018
Grant date	Nov 6, 2018

Abstract

This disclosure provides LOX1 (LOX1) binding proteins such as anti-LOX1 antibodies, and compositions and methods for making these binding proteins. In certain aspects the LOX1-binding proteins provided herein, inhibit, or antagonize LOX1 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating conditions associated with atherosclerosis, thrombosis, coronary artery disease (CAD), ischemia (e.g., myocardial ischemia), infarction (e.g., myocardial infarction), acute coronary syndrome (ACS), stroke, reperfusion injury, restenosis, peripheral vascular disease, hypertension, heart failure, inflammation (e.g., chronic inflammation), angiogenesis, preeclampsia, cancer and other LOX1-mediated diseases and conditions.

First claim

The invention claimed is:

1. An isolated Lectin-like oxidized low density lipoprotein receptor-1 (LOX1) antibody comprising a set of complementary determining regions (CDRs): heavy chain variable region (VH)-CDR1, VH-CDR2, VH-CDR3, and light chain variable region (VL)-CDR1, VL-CDR2 and VL-CDR3, wherein:
(a) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO:1;
(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO:2;
(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO:3;
(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO:30;
(v) VL-CDR2 has the amino acid sequence of SEQ ID NO:31; and
(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO:32;

(b) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO:1;
(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO:5;
(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO:14;
(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO:30;
(v) VL-CDR2 has the amino acid sequence of SEQ ID NO:31; and
(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO:32;

(c) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO:38;
(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO:39;
(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO:44;
(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO:55;
(v) VL-CDR2 has the amino acid sequence of SEQ ID NO:60; and
(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO:61; or

(d) (i) VH-CDR1 has the amino acid sequence of SEQ ID NO:38;
(ii) VH-CDR2 has the amino acid sequence of SEQ ID NO:39;
(iii) VH-CDR3 has the amino acid sequence of SEQ ID NO:40;
(iv) VL-CDR1 has the amino acid sequence of SEQ ID NO:55;
(v) VL-CDR2 has the amino acid sequence of SEQ ID NO:56; and
(vi) VL-CDR3 has the amino acid sequence of SEQ ID NO:57.

2. The isolated LOX1 antibody of claim 1 , wherein the LOX1 antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL) selected from the group consisting of:
(a) a VH having the amino acid sequence of SEQ ID NO:4 and a VL having the amino acid sequence of SEQ ID NO:33;
(b) a VH having the amino acid sequence of SEQ ID NO:29 and a VL having the amino acid sequence of SEQ ID NO:33;
(c) a VH having the amino acid sequence of SEQ ID NO:41 and a VL having the amino acid sequence of SEQ ID NO:58 and
(d) a VH having the amino acid sequence of SEQ ID NO:54 and a VL having the amino acid sequence of SEQ ID NO:70.

3. The isolated LOX1 antibody of claim 2 , wherein the LOX1 antibody comprises a heavy chain variable region (VH) comprising SEQ ID NO:4 and a light chain variable region (VL) comprising SEQ ID NO:33.

4. The isolated LOX1 antibody of claim 1 , wherein the LOX1 antibody reduces, inhibits or antagonizes LOX1 activity.

5. The isolated LOX1 antibody of claim 1 , wherein the antibody is a monoclonal antibody, a recombinant antibody, a human antibody, a humanized antibody, a chimeric antibody, a bi-specific antibody, a multi-specific antibody, or a LOX1-binding antibody fragment.

6. The isolated LOX1 antibody of claim 5 , wherein the LOX1-binding antibody fragment is selected from the group consisting of a Fab fragment, a Fab′ fragment, a F(ab′)2 fragment, a Fv fragment, a diabody, or a single chain antibody molecule.

7. The isolated LOX1 antibody of claim 1 , wherein the LOX1 antibody further comprises a heavy chain immunoglobulin constant domain selected from the group consisting of:
(a) a human IgA constant domain
(b) a human IgD constant domain;
(c) a human IgE constant domain;
(d) a human IgG1 constant domain;
(e) a human IgG2 constant domain;
(f) a human IgG3 constant domain;
(g) a human IgG4 constant domain; and
(h) a human IgM constant domain.

8. The isolated LOX1 antibody of claim 1 , wherein the LOX1 antibody further comprises a light chain immunoglobulin constant domain selected from the group consisting of:
(a) a human Ig kappa constant domain; and
(b) a human Ig lambda constant domain.

9. The isolated LOX1 antibody of claim 1 , wherein the LOX1 antibody further comprises a human IgG1 heavy chain constant domain and a human lambda light chain constant domain.

10. The isolated LOX1 antibody of claim 9 , wherein the IgG1 heavy chain constant domain contains a mutation at positions 234, 235 and 331, wherein the position numbering is according to the EU index as in Kabat.

11. The isolated LOX1 antibody of claim 10 , wherein the IgG1 heavy chain constant domain contains the mutations L234F, L235E and P331S, wherein the position numbering is according to the EU index as in Kabat.

12. An isolated nucleic acid molecule or set of nucleic acid molecules encoding a LOX1 antibody according to claim 1 .

13. A vector comprising the nucleic acid molecule according to claim 12 .

14. A pharmaceutical composition comprising a LOX1 antibody according to claim 1 and a pharmaceutically acceptable carrier.

15. A method for treating, preventing and/or ameliorating a cardiovascular disease or condition associated with LOX1 in a subject, comprising administering to a subject in need thereof an effective amount of a composition comprising a LOX1 antibody of claim 1 .

16. The method of claim 15 , wherein the cardiovascular disease or condition is selected from the group consisting of atherosclerosis, thrombosis, coronary artery disease (CAD), ischemia, infarction, acute coronary syndrome (ACS), stroke, reperfusion injury, restenosis, peripheral vascular disease, hypertension, heart failure, and angiogenesis.

17. A method of reducing or inhibiting LOX1 activity in a subject having a cardiovascular disease or condition associated with LOX1 comprising administering an effective amount of a LOX1 antibody according to claim 1 .

18. A method for treating, preventing and/or ameliorating a cardiovascular disease or condition associated with LOX1 in a subject, comprising administering to a subject in need thereof an effective amount of a composition comprising a LOX1 antibody of claim 3 .

19. The method of claim 18 , wherein the cardiovascular disease or condition is selected from the group consisting of atherosclerosis, thrombosis, coronary artery disease (CAD), ischemia, infarction, acute coronary syndrome (ACS), stroke, reperfusion injury, restenosis, peripheral vascular disease, hypertension, heart failure, and angiogenesis.

20. A method of reducing or inhibiting LOX1 activity in a subject having a cardiovascular disease or condition associated with LOX1 comprising administering an effective amount of a LOX1 antibody according to claim 3 .

Assignees

• Medimmune Ltd

Inventors

• Buchanan Andrew
• Chodorge Matthieu
• Cariuk Peter
• Husmark Johanna
• Balendran Clare
• Pandey Deepesh
• Chang Fumin
• Berkowitz Daniel E
• Romer Lewis H

Classifications

• G01N33/575

  for cancer · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• G01N33/00

  Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00 · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• C12N5/00

  Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques A01H4/00) · CPC title